Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia; Barbara Reichert; Jeffrey F. Scott; Ashley N. Feneran; Jordan A. Kazakov; Kord Honda; Henry Koon; Meg R. Gerstenblith

doi:10.1007/s10147-019-01490-2

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Pooja H. Rambhia, Barbara Reichert, Jeffrey F. Scott, Ashley N. Feneran, Jordan A. Kazakov, Kord Honda, Henry Koon, Meg R. Gerstenblith

Research output: Contribution to journal › Review article › peer-review

Abstract

Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

Original language	English (US)
Pages (from-to)	1171-1181
Number of pages	11
Journal	International Journal of Clinical Oncology
Volume	24
Issue number	10
DOIs	https://doi.org/10.1007/s10147-019-01490-2
State	Published - Oct 1 2019
Externally published	Yes

Keywords

CTLA-4
Drug reactions
Immune checkpoint inhibitor
Melanoma
PD-1
Sarcoidosis-like granuloma

ASJC Scopus subject areas

Surgery
Hematology
Oncology

Access to Document

10.1007/s10147-019-01490-2

Cite this

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. / Rambhia, Pooja H.; Reichert, Barbara; Scott, Jeffrey F.; Feneran, Ashley N.; Kazakov, Jordan A.; Honda, Kord; Koon, Henry; Gerstenblith, Meg R.

In: International Journal of Clinical Oncology, Vol. 24, No. 10, 01.10.2019, p. 1171-1181.

Research output: Contribution to journal › Review article › peer-review

@article{126db2ee9db841e4a8126cbd2e606540,

title = "Immune checkpoint inhibitor-induced sarcoidosis-like granulomas",

abstract = "Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.",

keywords = "CTLA-4, Drug reactions, Immune checkpoint inhibitor, Melanoma, PD-1, Sarcoidosis-like granuloma",

author = "Rambhia, {Pooja H.} and Barbara Reichert and Scott, {Jeffrey F.} and Feneran, {Ashley N.} and Kazakov, {Jordan A.} and Kord Honda and Henry Koon and Gerstenblith, {Meg R.}",

note = "Funding Information: This study was funded by the Char and Chuck Fowler Foundation, RES119774. Funding Information: Author PHR declares that she has no conflict of interest. Author BR declares that she has no conflict of interest. Author JFS declares that he has no conflict of interest. Author ANF declares that she has no conflict of interest. Author JAK declares that he has no conflict of interest. Author KH declares that he has no conflict of interest. Author HK owns stock in Company BMS. Author MRG has received research grants from the Char and Chuck Fowler Family Foundation. Publisher Copyright: {\textcopyright} 2019, Japan Society of Clinical Oncology.",

year = "2019",

month = oct,

day = "1",

doi = "10.1007/s10147-019-01490-2",

language = "English (US)",

volume = "24",

pages = "1171--1181",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "10",

}

TY - JOUR

T1 - Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

AU - Rambhia, Pooja H.

AU - Reichert, Barbara

AU - Scott, Jeffrey F.

AU - Feneran, Ashley N.

AU - Kazakov, Jordan A.

AU - Honda, Kord

AU - Koon, Henry

AU - Gerstenblith, Meg R.

N1 - Funding Information: This study was funded by the Char and Chuck Fowler Foundation, RES119774. Funding Information: Author PHR declares that she has no conflict of interest. Author BR declares that she has no conflict of interest. Author JFS declares that he has no conflict of interest. Author ANF declares that she has no conflict of interest. Author JAK declares that he has no conflict of interest. Author KH declares that he has no conflict of interest. Author HK owns stock in Company BMS. Author MRG has received research grants from the Char and Chuck Fowler Family Foundation. Publisher Copyright: © 2019, Japan Society of Clinical Oncology.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

AB - Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.

KW - CTLA-4

KW - Drug reactions

KW - Immune checkpoint inhibitor

KW - Melanoma

KW - PD-1

KW - Sarcoidosis-like granuloma

UR - http://www.scopus.com/inward/record.url?scp=85069503866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069503866&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01490-2

DO - 10.1007/s10147-019-01490-2

M3 - Review article

C2 - 31321613

AN - SCOPUS:85069503866

VL - 24

SP - 1171

EP - 1181

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 10

ER -

Immune checkpoint inhibitor-induced sarcoidosis-like granulomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this